## HUM: Humana Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.03 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($249.16)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Humana Inc. $HUM Shares Purchased by VIRGINIA RETIREMENT SYSTEMS ET Al**
- Source: MarketBeat | 20251231T115749 | Somewhat-Bullish | Relevance: 100%
- VIRGINIA RETIREMENT SYSTEMS ET Al significantly increased its stake in Humana Inc. (NYSE:HUM) by 63.8% in the third quarter, now owning 188,664 shares valued at approximately $49.1 million. Humana exceeded Q3 earnings estimates with $3.24 EPS and reported $32.65 billion in revenue, an 11.1% year-over-year increase. Despite analyst consensus being a "Hold" rating with an average target price of $294.32, the company declared a quarterly dividend of $0.885 per share.

**2. Humana’s Stock Under Pressure: Can The Health Insurance Giant Reclaim Its Former Momentum?**
- Source: AD HOC NEWS | 20260102T041719 | Somewhat-Bearish | Relevance: 100%
- Humana's stock has been under pressure due to concerns over Medicare Advantage risks, medical cost trends, and reimbursement pressures. Despite a bearish one-year performance and cautious analyst sentiment, the company's core business model in U.S. seniors' healthcare remains structurally attractive. Future trajectory depends on medical cost normalization, strategic growth, and regulatory clarity.

**3. Humana’s Stock Under Pressure: Can The Health Insurance Giant Reclaim Its Former Momentum?**
- Source: AD HOC NEWS | 20260102T040808 | Somewhat-Bearish | Relevance: 100%
- Humana's stock has been trending downwards, reflecting investor concerns about Medicare Advantage and rising medical costs, placing it at a critical juncture. Despite mixed analyst sentiment and a soft near-term outlook, the company's long-term prospects are tied to healthcare demographics and its ability to manage costs effectively. The market is waiting for clearer evidence that cost pressures are subsiding before the stock can reclaim its former momentum.

**4. Humana Inc. $HUM Shares Acquired by Ethic Inc.**
- Source: MarketBeat | 20260101T092038 | Somewhat-Bullish | Relevance: 100%
- Ethic Inc. significantly increased its stake in Humana Inc. (NYSE:HUM) by 174.3% in the third quarter, acquiring an additional 6,084 shares to bring its total holdings to 9,575 shares, valued at approximately $2.49 million. Institutional investors collectively hold 92.38% of Humana's stock, with major increases from Vanguard Group Inc., Dodge & Cox, and State Street Corp. Humana surpassed Q3 earnings estimates with EPS of $3.24 and revenue up 11.1% to $32.65 billion, and maintains a "Hold" consensus analyst rating with a target price of $294.32.

**5. Ninety One UK Ltd Makes New $18.61 Million Investment in Humana Inc. $HUM**
- Source: MarketBeat | 20260102T111715 | Bullish | Relevance: 97%
- Ninety One UK Ltd has made a new investment of $18.61 million in Humana Inc. (NYSE: HUM), acquiring 71,543 shares. This positions Ninety One UK Ltd as a significant stakeholder, owning approximately 0.06% of the company. Other institutional investors also adjusted their holdings, with Humana reporting strong quarterly earnings and a declared dividend.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Morgan Stanley | $262 | $277 | -5% |
| 2025-12-05 | Jefferies | $313 | $253 | +24% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |
| 2025-12-05 | Jefferies | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 5 ($1.54M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.3%)
- Dodge & Cox Inc.: 9.4% (-0.1%)
- JPMORGAN CHASE & CO: 8.4% (+237.0%)
- Blackrock Inc.: 8.3% (-3.0%)
- State Street Corpora: 4.5% (-0.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +2.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Balance sheet: strong liquidity (2.0x). Insider selling cluster ($1.5M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $31.8B |
| Beta | 0.47 |
| 52W Range | $206.87 - $315.35 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 21.2 |
| Current P/E | 15.5 |
| YoY Growth | -27.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 0.1% to 2.7% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.3pp (needs >4.0% for momentum thesis). MRS_5 at 2.7% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.68% (CS: 77) | Neutral |
| RSI_14 | 56.9 | Neutral |
| MACD Histogram | 0.12 | Bullish |
| vs SMA20 | 1.019x | Above |
| vs SMA50 | 1.027x | Above |
| vs SMA200 | 1.022x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $264.48
- **Stop Loss:** $249.16 (5.8% risk)
- **Target:** $295.12 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 93
- **Position Value:** $24,596.64
- **Portfolio %:** 24.60%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-11 (Est: $-3.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.83 | $3.24 | +14.6% |
| 2025Q2 | $5.87 | $6.27 | +6.9% |
| 2025Q1 | $10.07 | $11.58 | +15.0% |
| 2024Q4 | $-2.12 | $-2.16 | -1.9% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*